Participants 0 121 5
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy
Participants 199 287 5
Poor prognosis patients with bulky stage III locally advanced non-small-cell lung cancer
Participants 414 566 4
inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL)
Participants 576 655 6
A total of 188 poor prognosis patients recruited in a randomized clinical trial
Participants 927 1014 3
patients with tumors larger than 7 cm (N = 108) versus tumors 7 cm or smaller (N = 76).
Participants 1606 1693 3
patients with poor prognosis and inoperable locally advanced non-small-cell lung cancer
